Non-Toxic Disinfectant Reported to Kill Bubonic Plague Bacteria

Article

ALPINE, Utah -- American Biotech Labs recently completed a series of tests at a level three laboratory using its newly approved medical disinfectant ASAP-AGX-32. The product was tested against a concentration of 81,000,000 Y. pestis bacteria per milliliter. It killed all of them in less than two minutes.

Y. pestis is a bacterium that causes Bubonic Plague, also known as the black death. It killed one third of the population of Europe in the 14th century, and even today can kill 60 percent of untreated victims in three to five days. While there have been sporadic outbreaks in the United States, a more serious concern is the potential for weaponized Plague.

Said Keith Moeller, vice president of American Biotech Labs, "The ASAP-AGX-32 product has already been approved by the Environmental Protection Agency (EPA) for use against gram negative bacteria and Y. pestis is a gram negative bacterium. We wanted to test the limits of the product's capability, and we are delighted with the results. A normal in vitro (test tube) bacterial test uses a load of 500,000 bacteria per milliliter. The level of plague causing bacteria in our sample was 160 times that normal amount. The ASAP-AGX-32 disinfectant killed the bacteria in less than two minutes."

The ASAP-AGX-32 (EPA registration No. 73499-2) is unique in that it has no color or odor. Unlike other disinfectants, the ASAP ASAP-AGX-32 can be used or sprayed around both adults and children with no toxic effect. The product is not known to irritate the skin, eyes, nose, or lungs. To date, this product has killed every strain of every bacterium on which it has been tested. It has received EPA approval for use against the most deadly bacteria, including gram negative, gram positive and even nosocomial or hospital acquired (superbug) pathogens. The product has been approved for use as a broad spectrum, general use surface disinfectant in homes, hospitals, and medical settings.

Source: Clifton Mining Company

Related Videos
Jill Holdsworth, MS, CIC, FAPIC, CRCST, NREMT, CHL
Jill Holdsworth, MS, CIC, FAPIC, CRCSR, NREMT, CHL, and Katie Belski, BSHCA, CRCST, CHL, CIS
Baby visiting a pediatric facility  (Adobe Stock 448959249 by Rawpixel.com)
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Picture at AORN’s International Surgical Conference & Expo 2024
Infection Control Today and Contagion are collaborating for Rare Disease Month.
Related Content